Hemophilia A Gene Therapy: BioMarin In Lead, Sangamo ‘Prays’ For Superior Results

Long-Term Efficacy Doubts Linger For Valrox

 
• By Andrew McConaghie
  
Jefferies_Lobby
BioMarin and Sangamo were both presenting at the Jefferies conference in London
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies